Sažetak
Background: Hepatocellular carcinoma (HCC) is characterized by a chronic inflammatory and immunologically dysregulated microenvironment. Circulating immune-inflammatory biomarkers reflect systemic biochemical and immune alterations and may provide laboratory-accessible indicators for prognosis assessment. However, the prognostic value of interleukin-6 (IL-6) and the systemic immune-inflammation index (SII) in HCC patients receiving immune checkpoint inhibitors (ICIs) remains incompletely defined.
Methods: A comprehensive literature search was conducted across PubMed, Embase, Web of Science, the Cochrane Library, CNKI, and Wanfang Data to identify cohort studies evaluating circulating IL-6 and/or SII in HCC patients treated with ICIs. Hazard ratios (HRs) with 95% confidence intervals (CIs) for progression-free survival (PFS) and overall survival (OS) were pooled using fixed- or random-effects models. Subgroup and sensitivity analyses were performed to explore sources of heterogeneity.
Results: Twelve studies involving 1,508 patients were included. Elevated circulating IL-6 levels were significantly associated with poorer PFS (HR = 1.91, 95% CI 1.40–2.60) and OS (HR = 2.13, 95% CI 1.52–2.97), with robust results across sensitivity analyses. In contrast, the prognostic value of SII was context-dependent. Higher SII was significantly associated with shorter PFS in non-100% hepatitis B virus–related HCC populations and with poorer OS in patients receiving combined local treatment, while no significant associations were observed in other subgroups.
Conclusions: Circulating IL-6 serves as a stable immune-biochemical prognostic biomarker in HCC patients treated with ICIs, whereas the prognostic relevance of SII is modulated by disease etiology and treatment modality. These findings provide laboratory-relevant biochemical evidence supporting the integration of circulating immune-inflammatory markers into prognostic evaluation frameworks for HCC.
Ključne reči
Array
Array
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.